Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GEMTUZUMAB OZOGAMICIN Cause Bone marrow failure? 80 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 80 reports of Bone marrow failure have been filed in association with GEMTUZUMAB OZOGAMICIN (Mylotarg). This represents 4.4% of all adverse event reports for GEMTUZUMAB OZOGAMICIN.

80
Reports of Bone marrow failure with GEMTUZUMAB OZOGAMICIN
4.4%
of all GEMTUZUMAB OZOGAMICIN reports
19
Deaths
43
Hospitalizations

How Dangerous Is Bone marrow failure From GEMTUZUMAB OZOGAMICIN?

Of the 80 reports, 19 (23.8%) resulted in death, 43 (53.8%) required hospitalization, and 14 (17.5%) were considered life-threatening.

Is Bone marrow failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GEMTUZUMAB OZOGAMICIN. However, 80 reports have been filed with the FAERS database.

What Other Side Effects Does GEMTUZUMAB OZOGAMICIN Cause?

Febrile neutropenia (412) Pyrexia (138) Sepsis (122) Thrombocytopenia (117) Venoocclusive liver disease (117) Off label use (88) Drug ineffective (87) Death (81) Neutropenia (68) Septic shock (59)

What Other Drugs Cause Bone marrow failure?

CYCLOPHOSPHAMIDE (1,834) METHOTREXATE (1,401) ETOPOSIDE (1,081) RITUXIMAB (1,060) CYTARABINE (1,052) VINCRISTINE (1,001) DOXORUBICIN (1,000) PALBOCICLIB (951) CARBOPLATIN (855) BEVACIZUMAB (835)

Which GEMTUZUMAB OZOGAMICIN Alternatives Have Lower Bone marrow failure Risk?

GEMTUZUMAB OZOGAMICIN vs GEMZAR GEMTUZUMAB OZOGAMICIN vs GENTAMICIN GEMTUZUMAB OZOGAMICIN vs GEODON GEMTUZUMAB OZOGAMICIN vs GILENYA GEMTUZUMAB OZOGAMICIN vs GILOTRIF

Related Pages

GEMTUZUMAB OZOGAMICIN Full Profile All Bone marrow failure Reports All Drugs Causing Bone marrow failure GEMTUZUMAB OZOGAMICIN Demographics